Dare Bioscience, Inc. — Q2 2018 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2018. Dare is a clinical-stage biopharmaceutical company developing reproductive-health products; it reported no revenue from its primary business to date.
Financial results and liquidity
- Revenue: $0 for the three and six months ended June 30, 2018.
- Q2 operating expenses: $3.62 million, including $2.22 million of research and development, $1.16 million of general and administrative expense, and $250,000 of license expense. Q2 net loss was $3.58 million, or $0.32 per share.
- First-half results: Operating expenses were $11.30 million, including a $5.19 million goodwill impairment charge. Net loss was $11.25 million, or $1.13 per share.
- Cash and liquidity: Cash and cash equivalents were $12.45 million at June 30, versus $7.56 million at December 31, 2017. Working capital was approximately $11.6 million. Current liabilities were $1.27 million, primarily accounts payable and accrued expenses.
- Cash flows, first half: $4.81 million used in operations and $460,000 used in investing; $10.20 million provided by financing, mainly equity offerings. Cash increased by $4.89 million.
- Debt and margins: No debt balance is presented on the June 30 balance sheet. Gross margins are not applicable because the company had no revenue.
Changes versus the prior comparable period
Q2 net loss increased from $498,000 in 2017 to $3.58 million in 2018; first-half net loss increased from $742,000 to $11.25 million. Expenses rose as Dare expanded product development, licensing, and public-company operations. The first-half 2018 comparison also includes a $5.19 million goodwill impairment and Pear Tree acquisition costs. Comparisons are limited: 2018 reflects operations following the July 2017 Cerulean/Private Dare transaction, while 2017 reflects the private Dare business.
Outlook, management commentary, and key risks
- Management expected operating losses to continue for at least several years and said cash on hand was expected to fund planned operations for at least 12 months from the filing date. The estimate depends on assumptions and could change with clinical plans, acquisitions, or development costs.
- Management said available funds were expected to support completion of the Ovaprene postcoital test (PCT) trial and advancement of topical 5% sildenafil citrate cream into a Phase 2b trial. Ovaprene PCT data was expected in the second half of 2019; timing of sildenafil studies depended in part on FDA guidance.
- Dare stated it would need additional capital. Failure to obtain financing could require delaying, scaling back, or ending programs, or ceasing operations; equity financing could dilute shareholders.
- Portfolio activity included the May 2018 acquisition of Pear Tree and rights to PT-101, licensing of preclinical intravaginal-ring assets from Juniper, and development options for long-acting injectable contraceptives with Orbis. A Hydra asset acquisition occurred in July, after quarter-end.
- License arrangements include potential milestone, royalty, and other payments, many contingent on clinical, regulatory, or commercial progress. The NIH award began with $224,665 of an anticipated $1.9 million; the balance was conditional, including on research assessment and funding availability.
- The February 2018 offering included warrants for up to 3.5 million shares, with anti-dilution provisions. The company also reported issuing 5.0 million common shares in the offering and selling 375,000 shares through its ATM program during the first half.
- No material pending legal proceedings were reported. Management concluded disclosure controls were effective as of June 30, 2018.
Important facts for investors to verify
- Whether the reported cash runway remains adequate as clinical programs and portfolio costs evolve, and what financing may be needed.
- Progress, enrollment, results, and regulatory plans for the Ovaprene PCT trial and the topical sildenafil program.
- The terms and potential financial impact of licensing and acquisition obligations, including milestone and royalty commitments.
- Potential dilution from outstanding warrants, options, and future equity financing.
- The assumptions and valuation supporting the $5.19 million goodwill impairment and the extent to which unusual acquisition-related costs affect reported results.